Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

FDA: Cybersecurity is an ever-present risk for medical devices

US regulator issues new guidance for manufacturers

- PMLiVE

J&J partner drive nets 15 new deals, and another NASH drug

Fosters new collaborations in treatment-resistant depression, infectious diseases and cancer

- PMLiVE

Amgen wins block on sales of Sanofi/Regeneron’s Praluent

Repatha maintains patent rights but Sanofi and Regeneron set to appeal

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Speaking the language of effective communications

Crafting appropriate communications still requires the fundamentals to be done brilliantly, but increasingly a smarter integrated approach is key, says Claire Gillis

- PMLiVE

Merck & Co’s Dr Daniel Pascheles joins Molekule Consulting

He becomes the biopharma services provider’s CEO

J&J collaborates on consumer health device accelerator

Partners with Shenzhen-based investor firm HAX

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

- PMLiVE

Eisai takes control of weight loss drug Belviq from Arena

Buys global rights to obesity drug in $49m deal to expedite roll-out and boost sales

- PMLiVE

Greece steps up Novartis corruption probe after suicide attempt

Accelerates investigation into whether Novartis paid bribes to doctors and civil servants to drive sales

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

Wilmington Healthcare

- PMLiVE

The EarthWorks: New ways to improve patient care

How marketing efforts in the pharma industry can improve outcomes while delivering increased value to healthcare providers and payers

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links